RYTM - Rhythm posts promising obesity study results at ENDO 2021

Rhythm Pharmaceuticals (RYTM), over the weekend, posted data from its mid and late stage studies of anti-obesity medication setmelanotide at the 103rd Annual Meeting and Expo of the Endocrine Society ((ENDO 2021)).The presentations included data from a Phase 2 study of setmelanotide in people living with heterozygous ((HET)) obesity due to genetic variants in one of two alleles of the POMC, PCSK1 or LEPR gene and topline data from Rhythm’s Phase 3 trial of the medicine in patients with Bardet-Biedl syndrome ((BBS)) or Alström syndrome.In the mid-stage HET obesity study, the primary endpoint was mean percent change from baseline in body weight, and 34.3 percent of all patients in the study (12/35) responded with 5 percent or greater weight loss at three months. Mean weight loss among responders was -10.1 percent at three months.“These data give us further confidence as we advance setmelanotide through a multi-faceted clinical development program designed to address a range of rare genetic

For further details see:

Rhythm posts promising obesity study results at ENDO 2021